Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) had its target price hoisted by Laidlaw from $75.00 to $105.00 in a note issued to investors on Thursday, MarketBeat reports. The firm currently has a "buy" rating on the stock. Laidlaw's target price would indicate a potential upside of 46.96% from the company's current price.
Several other research analysts also recently weighed in on the company. Stifel Nicolaus assumed coverage on Soleno Therapeutics in a research note on Wednesday, March 5th. They set a "buy" rating and a $74.00 target price for the company. Robert W. Baird boosted their price objective on Soleno Therapeutics from $72.00 to $102.00 and gave the stock an "outperform" rating in a research note on Thursday. HC Wainwright restated a "buy" rating and issued a $70.00 target price on shares of Soleno Therapeutics in a research report on Monday, March 3rd. Cantor Fitzgerald lifted their price target on Soleno Therapeutics from $67.00 to $123.00 and gave the stock an "overweight" rating in a research note on Thursday. Finally, Lifesci Capital raised Soleno Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 4th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Soleno Therapeutics presently has an average rating of "Buy" and an average target price of $98.86.
Read Our Latest Analysis on Soleno Therapeutics
Soleno Therapeutics Stock Down 0.8 %
Shares of NASDAQ:SLNO traded down $0.54 during trading on Thursday, hitting $71.45. 4,004,553 shares of the stock traded hands, compared to its average volume of 649,580. The company has a fifty day moving average price of $48.94 and a two-hundred day moving average price of $50.08. Soleno Therapeutics has a 52-week low of $36.61 and a 52-week high of $73.97. The company has a market cap of $3.28 billion, a price-to-earnings ratio of -21.52 and a beta of -1.70.
Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($1.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.41). On average, equities research analysts predict that Soleno Therapeutics will post -3.72 EPS for the current fiscal year.
Insiders Place Their Bets
In other Soleno Therapeutics news, insider Kristen Yen sold 2,340 shares of Soleno Therapeutics stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $46.18, for a total value of $108,061.20. Following the sale, the insider now owns 76,605 shares in the company, valued at $3,537,618.90. The trade was a 2.96 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO James H. Mackaness sold 4,083 shares of the firm's stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $45.41, for a total value of $185,409.03. Following the sale, the chief financial officer now directly owns 115,089 shares of the company's stock, valued at $5,226,191.49. The trade was a 3.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 17,360 shares of company stock valued at $790,119 in the last three months. 12.30% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Soleno Therapeutics
Institutional investors have recently bought and sold shares of the company. AlphaQuest LLC grew its holdings in shares of Soleno Therapeutics by 1,154.4% in the fourth quarter. AlphaQuest LLC now owns 715 shares of the company's stock valued at $32,000 after purchasing an additional 658 shares in the last quarter. US Bancorp DE purchased a new position in Soleno Therapeutics in the fourth quarter valued at $34,000. Avanza Fonder AB purchased a new stake in Soleno Therapeutics during the 4th quarter worth about $76,000. Springhill Fund Asset Management HK Co Ltd purchased a new stake in Soleno Therapeutics during the 4th quarter worth about $81,000. Finally, Avior Wealth Management LLC acquired a new stake in Soleno Therapeutics in the 4th quarter valued at about $89,000. 97.42% of the stock is owned by institutional investors and hedge funds.
About Soleno Therapeutics
(
Get Free Report)
Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
Further Reading
Before you consider Soleno Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Soleno Therapeutics wasn't on the list.
While Soleno Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
